A citation-based method for searching scientific literature

John G Moffat, Fabien Vincent, Jonathan A Lee, Jörg Eder, Marco Prunotto. Nat Rev Drug Discov 2017
Times Cited: 272







List of co-cited articles
581 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


How were new medicines discovered?
David C Swinney, Jason Anthony. Nat Rev Drug Discov 2011
28

The discovery of first-in-class drugs: origins and evolution.
Jörg Eder, Richard Sedrani, Christian Wiesmann. Nat Rev Drug Discov 2014
229
16

Phenotypic screening in cancer drug discovery - past, present and future.
John G Moffat, Joachim Rudolph, David Bailey. Nat Rev Drug Discov 2014
239
11

Cell Painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes.
Mark-Anthony Bray, Shantanu Singh, Han Han, Chadwick T Davis, Blake Borgeson, Cathy Hartland, Maria Kost-Alimova, Sigrun M Gustafsdottir, Christopher C Gibson, Anne E Carpenter. Nat Protoc 2016
175
11

Phenotypic screens as a renewed approach for drug discovery.
Wei Zheng, Natasha Thorne, John C McKew. Drug Discov Today 2013
213
10

Target identification and mechanism of action in chemical biology and drug discovery.
Monica Schenone, Vlado Dančík, Bridget K Wagner, Paul A Clemons. Nat Chem Biol 2013
446
9

Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay.
Daniel Martinez Molina, Rozbeh Jafari, Marina Ignatushchenko, Takahiro Seki, E Andreas Larsson, Chen Dan, Lekshmy Sreekumar, Yihai Cao, Pär Nordlund. Science 2013
758
9

Developing predictive assays: the phenotypic screening "rule of 3".
Fabien Vincent, Paula Loria, Marko Pregel, Robert Stanton, Linda Kitching, Karl Nocka, Regis Doyonnas, Claire Steppan, Adam Gilbert, Thomas Schroeter,[...]. Sci Transl Med 2015
99
9

Identifying compound efficacy targets in phenotypic drug discovery.
Markus Schirle, Jeremy L Jenkins. Drug Discov Today 2016
82
9

Screening out irrelevant cell-based models of disease.
Peter Horvath, Nathalie Aulner, Marc Bickle, Anthony M Davies, Elaine Del Nery, Daniel Ebner, Maria C Montoya, Päivi Östling, Vilja Pietiäinen, Leo S Price,[...]. Nat Rev Drug Discov 2016
232
8

Tracking cancer drugs in living cells by thermal profiling of the proteome.
Mikhail M Savitski, Friedrich B M Reinhard, Holger Franken, Thilo Werner, Maria Fälth Savitski, Dirk Eberhard, Daniel Martinez Molina, Rozbeh Jafari, Rebecca Bakszt Dovega, Susan Klaeger,[...]. Science 2014
415
7


Drug repurposing: progress, challenges and recommendations.
Sudeep Pushpakom, Francesco Iorio, Patrick A Eyers, K Jane Escott, Shirley Hopper, Andrew Wells, Andrew Doig, Tim Guilliams, Joanna Latimer, Christine McNamee,[...]. Nat Rev Drug Discov 2019
871
6

Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy.
Nikolai A Naryshkin, Marla Weetall, Amal Dakka, Jana Narasimhan, Xin Zhao, Zhihua Feng, Karen K Y Ling, Gary M Karp, Hongyan Qi, Matthew G Woll,[...]. Science 2014
282
6

SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice.
James Palacino, Susanne E Swalley, Cheng Song, Atwood K Cheung, Lei Shu, Xiaolu Zhang, Mailin Van Hoosear, Youngah Shin, Donovan N Chin, Caroline Gubser Keller,[...]. Nat Chem Biol 2015
213
6

Diagnosing the decline in pharmaceutical R&D efficiency.
Jack W Scannell, Alex Blanckley, Helen Boldon, Brian Warrington. Nat Rev Drug Discov 2012
808
6

Phase II and phase III failures: 2013-2015.
Richard K Harrison. Nat Rev Drug Discov 2016
169
6

Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA).
Hasane Ratni, Martin Ebeling, John Baird, Stefanie Bendels, Johan Bylund, Karen S Chen, Nora Denk, Zhihua Feng, Luke Green, Melanie Guerard,[...]. J Med Chem 2018
122
6

Target deconvolution from phenotype-based drug discovery by using chemical proteomics approaches.
Kazuishi Kubota, Masanori Funabashi, Yuji Ogura. Biochim Biophys Acta Proteins Proteom 2019
32
18

A comprehensive map of molecular drug targets.
Rita Santos, Oleg Ursu, Anna Gaulton, A Patrícia Bento, Ramesh S Donadi, Cristian G Bologa, Anneli Karlsson, Bissan Al-Lazikani, Anne Hersey, Tudor I Oprea,[...]. Nat Rev Drug Discov 2017
746
6

Generating Focused Molecule Libraries for Drug Discovery with Recurrent Neural Networks.
Marwin H S Segler, Thierry Kogej, Christian Tyrchan, Mark P Waller. ACS Cent Sci 2018
284
6

Deep learning.
Yann LeCun, Yoshua Bengio, Geoffrey Hinton. Nature 2015
6

How to improve R&D productivity: the pharmaceutical industry's grand challenge.
Steven M Paul, Daniel S Mytelka, Christopher T Dunwiddie, Charles C Persinger, Bernard H Munos, Stacy R Lindborg, Aaron L Schacht. Nat Rev Drug Discov 2010
6

Innovation in the pharmaceutical industry: New estimates of R&D costs.
Joseph A DiMasi, Henry G Grabowski, Ronald W Hansen. J Health Econ 2016
895
6


Applications of chemogenomic library screening in drug discovery.
Lyn H Jones, Mark E Bunnage. Nat Rev Drug Discov 2017
77
6

Can the pharmaceutical industry reduce attrition rates?
Ismail Kola, John Landis. Nat Rev Drug Discov 2004
5



Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry.
Holger Franken, Toby Mathieson, Dorothee Childs, Gavain M A Sweetman, Thilo Werner, Ina Tögel, Carola Doce, Stephan Gade, Marcus Bantscheff, Gerard Drewes,[...]. Nat Protoc 2015
200
5

Deep learning enables rapid identification of potent DDR1 kinase inhibitors.
Alex Zhavoronkov, Yan A Ivanenkov, Alex Aliper, Mark S Veselov, Vladimir A Aladinskiy, Anastasiya V Aladinskaya, Victor A Terentiev, Daniil A Polykovskiy, Maksim D Kuznetsov, Arip Asadulaev,[...]. Nat Biotechnol 2019
174
5

Automatic Chemical Design Using a Data-Driven Continuous Representation of Molecules.
Rafael Gómez-Bombarelli, Jennifer N Wei, David Duvenaud, José Miguel Hernández-Lobato, Benjamín Sánchez-Lengeling, Dennis Sheberla, Jorge Aguilera-Iparraguirre, Timothy D Hirzel, Ryan P Adams, Alán Aspuru-Guzik. ACS Cent Sci 2018
459
5

Target validation using chemical probes.
Mark E Bunnage, Eugene L Piatnitski Chekler, Lyn H Jones. Nat Chem Biol 2013
248
5

Impact of high-throughput screening in biomedical research.
Ricardo Macarron, Martyn N Banks, Dejan Bojanic, David J Burns, Dragan A Cirovic, Tina Garyantes, Darren V S Green, Robert P Hertzberg, William P Janzen, Jeff W Paslay,[...]. Nat Rev Drug Discov 2011
566
5

Hit Triage and Validation in Phenotypic Screening: Considerations and Strategies.
Fabien Vincent, Paula M Loria, Andrea D Weston, Claire M Steppan, Regis Doyonnas, Yue-Ming Wang, Kristin L Rockwell, Marie-Claire Peakman. Cell Chem Biol 2020
10
50

How Phenotypic Screening Influenced Drug Discovery: Lessons from Five Years of Practice.
Dorothea Haasen, Ulrich Schopfer, Christophe Antczak, Chantale Guy, Florian Fuchs, Paul Selzer. Assay Drug Dev Technol 2017
30
16

Drug repositioning: identifying and developing new uses for existing drugs.
Ted T Ashburn, Karl B Thor. Nat Rev Drug Discov 2004
5

The ChEMBL database in 2017.
Anna Gaulton, Anne Hersey, Michał Nowotka, A Patrícia Bento, Jon Chambers, David Mendez, Prudence Mutowo, Francis Atkinson, Louisa J Bellis, Elena Cibrián-Uhalte,[...]. Nucleic Acids Res 2017
736
4

A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles.
Aravind Subramanian, Rajiv Narayan, Steven M Corsello, David D Peck, Ted E Natoli, Xiaodong Lu, Joshua Gould, John F Davis, Andrew A Tubelli, Jacob K Asiedu,[...]. Cell 2017
777
4

Scalable Production of iPSC-Derived Human Neurons to Identify Tau-Lowering Compounds by High-Content Screening.
Chao Wang, Michael E Ward, Robert Chen, Kai Liu, Tara E Tracy, Xu Chen, Min Xie, Peter Dongmin Sohn, Connor Ludwig, Anke Meyer-Franke,[...]. Stem Cell Reports 2017
79
5

An analysis of the attrition of drug candidates from four major pharmaceutical companies.
Michael J Waring, John Arrowsmith, Andrew R Leach, Paul D Leeson, Sam Mandrell, Robert M Owen, Garry Pairaudeau, William D Pennie, Stephen D Pickett, Jibo Wang,[...]. Nat Rev Drug Discov 2015
534
4

Clinical development success rates for investigational drugs.
Michael Hay, David W Thomas, John L Craighead, Celia Economides, Jesse Rosenthal. Nat Biotechnol 2014
4

Target-based drug discovery: is something wrong?
Frank Sams-Dodd. Drug Discov Today 2005
309
4

ChEMBL: a large-scale bioactivity database for drug discovery.
Anna Gaulton, Louisa J Bellis, A Patricia Bento, Jon Chambers, Mark Davies, Anne Hersey, Yvonne Light, Shaun McGlinchey, David Michalovich, Bissan Al-Lazikani,[...]. Nucleic Acids Res 2012
4


Molecular Phenotyping Combines Molecular Information, Biological Relevance, and Patient Data to Improve Productivity of Early Drug Discovery.
Faye Marie Drawnel, Jitao David Zhang, Erich Küng, Natsuyo Aoyama, Fethallah Benmansour, Andrea Araujo Del Rosario, Sannah Jensen Zoffmann, Frédéric Delobel, Michael Prummer, Franziska Weibel,[...]. Cell Chem Biol 2017
19
21



Emerging Approaches for the Identification of Protein Targets of Small Molecules - A Practitioners' Perspective.
Kenneth M Comess, Shaun M McLoughlin, Jon A Oyer, Paul L Richardson, Henning Stöckmann, Anil Vasudevan, Scott E Warder. J Med Chem 2018
33
12

Functional genomics to uncover drug mechanism of action.
Sebastian M B Nijman. Nat Chem Biol 2015
44
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.